ImPact enters partnership for pathologic myopia therapy development
2023-08-14
临床3期上市批准
Preview
来源: Pharmaceutical Technology
Pathologic myopia, or myopic macular degeneration, is a severe eye disease. Credit: Serafino Mozzo / Shutterstock.com.
Israeli biotech organisation ImPact Biotech has entered a research partnership with Maastricht University in the Netherlands to develop a therapy for arresting the progression of pathologic myopia or myopic macular degeneration (MMD), a severe eye disease.
The organisation will work with two researchers from the university, associate professor Dr Mor Dickman and MERLN Institute associate professor Dr Vanessa LaPointe.
Recommended Reports
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Radiprodil in Neurodegenerative Diseases GlobalData
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Spebrutinib Besylate in Follicular Lymphoma GlobalData
View allCompanies IntelligenceMaastricht UniversityImpact BioTech LtdView all
The parties will leverage the Padeliporfin vascular targeted photodynamic (VTP) therapy platform of ImPact for developing the treatment.
Padeliporfin has received the European Medicines Agency’s approval for usage in low-risk prostate cancer patients.
It is currently being evaluated in a Phase III clinical trial for treating low-grade upper tract urothelial carcinoma.
The organisation also plans to commence further studies of Padeliporfin in patients with non-small cell lung cancer and pancreatic cancer.
ImPact Biotech Research and Development global head Dr David Perry stated: “We look forward to collaborating with Maastricht University’s Drs LaPointe and Dickman on this important research collaboration to address the huge unmet medical need in progressive myopia while leveraging our Padeliporfin VTP technology to help patients afflicted with this highly debilitating condition.
“Initial results with our Padeliporfin approach are very encouraging and we are looking forward to progressing it rapidly towards clinical research by growing our understanding of the disease and the potential interventions to change its course with the contribution of this collaboration.”
The organisation is also partnering with research institutes and specialists in associated areas to analyse its platform’s potential to treat pathological myopia.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。